Urethra transitional cell carcinoma

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This early-phase trial is testing whether giving two immunotherapy drugs (durvalumab and tremelimumab) before surgery can help patients with aggressive bladder cancer who cannot take standard chemotherapy. The study involves 54 participants and primarily looks at safety and how t…

This early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…

This study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…

This early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…

This phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from growing after initial chemotherapy. About 654 patients will receive either the combination or avelumab alone as maintenance therapy. The goal is to s…

This study looks at whether people with advanced bladder cancer can stop taking immunotherapy drugs (like pembrolizumab or nivolumab) after about a year instead of continuing indefinitely. The goal is to see if stopping early leads to similar survival rates while reducing side ef…

This phase 2 trial is testing whether adding propranolol, a common blood pressure drug, to standard immunotherapy can help control advanced bladder cancer. The study enrolled 6 adults with urothelial carcinoma that has spread or cannot be removed by surgery. Researchers are prima…

This early-stage trial tests a new drug called DECOY20, which is designed to wake up the immune system to fight cancer. It is being tested alone or with another drug (tislelizumab) in 120 adults with advanced solid tumors like liver, lung, or colorectal cancer. The main goals are…

This early-phase trial tests whether adding the immunotherapy drug pembrolizumab to standard platinum-based chemotherapy can help people with rare, aggressive small cell or neuroendocrine cancers of the bladder or prostate. The study includes 15 participants whose cancer has spre…

This study compares giving chemotherapy before surgery versus surgery alone for patients with upper tract urothelial cancer. About 120 participants will be assigned to one of two groups based on their choice and doctor's evaluation. The goal is to see if the chemo-surgery combo l…

This small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…